MedTrace Logo

Beta-glucans for Hospitalised Patients With COVID-19

NCT05465798 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-12-13

No results posted yet for this study

Summary

This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.

Conditions

Interventions

DRUG

MC 3x3

Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.

DRUG

Placebo

Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.

Sponsors & Collaborators

  • Concentra Educación e Investigación Biomédica

    collaborator UNKNOWN

  • Wohlstand Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Alejandra Correa, MD · Hospital Geriátrico Paz de La Tarde

  • Maria José Ruz · Hospital Gustavo Fricke

  • Mario Reyes · Science & Cash Group SpA

  • Felipe Martinez, MD, MSc · Concentra Investigacion

  • Michael Araya · Hospital Gustavo Fricke

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • Chile

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465798 on ClinicalTrials.gov